Anrotinib is a multi-target tyrosine kinase inhibitor, an orally administered small molecule drug that exerts an inhibitory effect on tumor angiogenesis and tumor cell proliferation by selectively inhibiting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) (7). Here, KDR is linked to neoplasm.